Mobile website
Archive > Volume 25 Issue 3 > 2018,25(3):240-245. DOI:10.3872/j.issn.1007-385X.2018.03.005 Prev Next
Basic Research
The effects of FANCF on paclitaxel-resistant triple negative breast cancer cell
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To establish paclitaxel(PTX)-resistant human triple negative breast cancer cell line and to examine the expres- sion profile of FA-related genes and FANCF, the correlation between the expression of FA-related genes, FANCF and PTX-resistance in breast cancer were further analyzed. Methods: PTX-resistant MDA-MB-231 cell line was established by means of long-term PTX-ex- posed culture. The sensitivity of the cells to paclitaxel was determined by the CCK8 assay. The cell cycle distribution was examined by flow cytometry after exposure to the paclitaxel. The expression of FA-related gene mRNA and FANCF protein were examined by using real time quantitative PCR and Western blotting. The expression of FANCF in the cells was reduced by RNAi interference technology and the effect of the RNAi was verified. Results: MDA-MB-231/PTX cell showed a 9.9-fold resistance to paclitaxel, indicating that the cell had acquired resistance to PTX. PTX treatment significantly induced G0/G1 arrest and the number of cells in phase S markedly de- creased after exposure to PTX. The mRNA and protein expression of FANCF was significantly higher in PTX-resistant cell than that in PTX-sensitve parental cell，Knockdown of FANCF induced apoptosis in MDA-MB-231/PTX cell as well as in parental cell. FANCF knockdown increased the sensitivity of paclitaxel to both MDA-MB-231 and MDA-MB-231/PTX cells (P<0.05 or P<0.01). Conclu- sion: FANCF played an important role in PTX resistance of the breast cancer cells and FANCF might be a target for therapy aimed at re- versing chemoresistance.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 81660472), the Yunnan Health System Leader Training Program (No. L-201212), and the Key Medical Laboratory Fund of Cell Therapy Technology Transfer of Yunnan Province （No. 2015DG034）
Clc Number:
